ECP 2023 Final Programme

Tuesday, 12 Sept 54 Scientific Programme a Tuesday OFP-09 Oral Free Paper Session 08:30–12:00 Liffey Hall 1 Breast Pathology Chairs: Balazs Acs, Sweden Grace Callagy, Ireland 001 08:30–08:40 Breast-conserving surgery in invasive lobular carcinoma of the breast after neoadjuvant chemotherapy Júlia Azevedo, Portugal M. Alzamora, A. Coutada, A. Lapa, L. Gonçalves, N. Coimbra, C. Leal 002 08:40–08:50 Analysis of discordant cases between tumour grade and risk categorisation using EndoPredict® in breast cancer Víctor Macarrón Aguilera, Spain A. Peláez-García, J. Sánchez-Méndez, L. Yébenes, A. Berjón, D. Hardisson 003 08:50–09:00 Intraoperative evaluation of sentinel lymph nodes after neoadjuvant therapy in breast cancer patients has low accuracy rate due to unique challenges Sunati Sahoo, USA M. Huerta-Rosario, R. Zhang, Y. Fang 004 09:00–09:10 TRPS1 is a highly sensitive marker for breast cancer: a tissue microarray study evaluating more than 19,000 tumors from 152 different tumor entities Maximilian Lennartz, Germany N. Blessin, C. Hube-Magg, T. Krech, A. Hinsch, E. Burandt, G. Sauter, R. Simon, P. Lebok, D. Dum, S. Minner, F. Jacobsen, T. Clauditz, C. Bernreuther, S. Steurer 005 09:10–09:20 Risk stratification in invasive lobular carcinoma of the breast by clinicopathologi- cal features and Prosigna-PAM50 multigene assay characterisation Joao Vaz Silva, Portugal A. Varelas, C. Escudeiro, M. Teixeira, C. Leal, N. Coimbra 006 09:20–09:30 Dako HercepTest (poly) allocates more cases to HER2-low group compared to ventana PATHWAY 4B5 anti-HER2 assay: a multicenter study on 116 invasive breast cancer cases Ozgur Can Eren, Turkey O. Taskin, M. Oktay, A. Baygul, F. Aktepe, N. Kapucuoglu 007 10:30–10:40 Multi-reader study of a fully automated artificial intelligence solution for HER2 IHC scoring in breast cancer biopsies Savitry Krishnamurthy, USA S. Schnitt, A. Vincent-Salomon, R. Canas- Marques, E. Colon, K. Kantekure, M. Maklakovski, W. Finck, J. Thomassin, Y. Globerson, L. Bien, M. Grinwald, M. Vecsler, C. Linhart, J. Sandbank 008 10:40–10:50 Agreement among 4 observers and 4 reading modalities for HER2 Low designa- tion of breast carcinoma Sharon Nofech-Mozes, Canada E. Olkhov-Mitsel, A. Plotkin, E. Slodkowska, F. Lu 009 10:50–11:00 Upgrade rate and predictive factors of fibroepithelial lesions of the breast to phyllodes tumour Reza Alaghehbandan, USA T. Salisbury, M. Zokaei Nikoo, G. Sokhanran, S. Koonmee 010 11:00–11:10 The assessment of tumour-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the Her2 status Semir Vranic, Qatar N. Kuzumova, I. Rose, Z. Gatalica 011 11:10–11:20 Heterogenous HER2 inter- and intra-labora- tory lower limit of detection Nils ‘t Hart, The Netherlands S. Sompuram, M. Eenkhoorn, D. Dabbs, S. Bogen